Volume 17, Number 5—May 2011
Genetic Characterization of West Nile Virus Lineage 2, Greece, 2010
We conducted a complete genome analysis of a West Nile virus detected in Culex pipiens mosquitoes during a severe outbreak of human West Nile disease in Greece 2010. The virus showed closest genetic relationship to the lineage 2 strain that emerged in Hungary in 2004; increased virulence may be associated with amino acid substitution H249P.
West Nile virus (WNV) is a flavivirus maintained in an enzootic cycle between bird amplifying hosts and ornithophilic mosquito vectors, mainly Culex species; humans, horses, and other mammals are incidental hosts. Although most human WNV infections remain subclinical, febrile illness develops in ≈20% of infected persons and neuroinvasive disease in <1%. Severe disease is more frequent among the elderly and immunocompromised (1).
WNV strains are classified into at least 7 putative genetic lineages (2). Lineage 1 strains are the most widespread, found in Africa, Europe, Asia, Australasia (“Kunjin virus”), and America, while lineage 2 strains are mainly distributed in sub-Saharan Africa and Madagascar. WNV of proposed lineage 3 (“Rabensburg virus”) is circulating in certain Culex and Aedes species mosquitoes in southern Moravia, Czech Republic, close to the Austrian border, without recognized pathogenicity for mammals (3). Strain LEIV-Krns88-190, isolated from Dermacentor marginatus ticks from the Caucasus represents proposed lineage 4 of WNV. A new lineage, lineage 5, has been proposed for Indian isolates previously comprising lineage 1c, and a reclassification as lineage 6 has been proposed for the Sarawak Kunjin virus strain, which is markedly different from the other Kunjin viruses. Furthermore, a seventh lineage has been suggested for the African Koutango virus, which is closely related to WNV (2), and an eighth lineage has been proposed on the basis of WNV sequences detected in Cx. pipiens mosquitoes captured in southern Spain in summer 2006 (4).
WNV strains differ considerably in virulence and neuroinvasiveness. Since neuroinvasive isolates mainly belonged to lineage 1, lineage 2 strains were previously considered to be less virulent. Recent studies, however, indicate that several highly virulent and neuroinvasive strains of lineage 2 WNV were detected in southern Africa (5).
Until 2004, only lineage 1 and 3 WNV strains had been found in Europe. A lineage 2 strain emerged in 2004 in Hungary in birds of prey (6), which established itself in the region and exhibited explosive geographic spread in 2008 throughout Hungary and into eastern Austria. Besides deaths in birds and domesticated mammals, human neurologic WNV cases have been diagnosed in the affected regions during the epidemic seasons since 2004. However, the human cases of WNV neuroinvasive disease have been comparatively rare and rather mild with no deaths.
In Greece, where WNV cases had not previously been reported, a 2007 study, conducted in an area near a delta where 4 rivers enter the Aegean Sea, 4 (1%) of 392 persons exhibited neutralizing WNV antibodies, 2 with high titers. These findings suggested that WNV, or an antigenically closely related flavivirus, circulates, at least locally, in rural areas in Greece (7). This area was the focus of a large WNV outbreak in summer–autumn 2010 (8). Up to October 4, 2010, a total of 191 neuroinvasive human cases have been laboratory diagnosed, with 32 deaths, all in elderly patients.
Soon after the first human cases were recognized, mosquitoes were trapped at the sites where the cases occurred and tested for WNV. One pool, consisting of 50 Cx. pipiens mosquitoes, trapped during the night of August 10, 2010, in Nea Santa (40.84194°N, 22.91499°E), a village 30 km northeast of Thessaloniki, was found to be positive for WNV RNA by reverse transcription–PCR. Sequencing of a 146-nt fragment of the nonstructural protein 5 (NS5) gene gave the first evidence that the virus belongs to lineage 2, and that it is highly similar to the strain that emerged in Hungary in 2004 and to isolates from fatal human and animal cases in South Africa (9). The purpose of this study was to establish the complete genomic sequence of the WNV identified in a pool of mosquitoes trapped at the site of an ongoing West Nile disease epidemic in humans, and investigate it for potential (neuro)virulence/pathogenicity markers.
To amplify overlapping PCR products of the WNV from the Greek outbreak, we used RNA from the above-mentioned mosquito pool and reverse transcription–PCRs designed for the amplification of the complete genome of lineage 2 WNV, which had emerged in Hungary in 2004 (strain goshawk-Hungary-2004, GenBank accession no. DQ116961; 6). Amplification products were directly sequenced in both directions; sequences were aligned and compiled, and an 11,028-nt continuous sequence was obtained, representing the nearly complete genome sequence of the virus, designated Nea Santa-Greece-2010. Because of the limited amount of sample material, the last 20 nt of the 5′ and 3′ ends were not determined by rapid amplification of cDNA ends. The nucleotide sequence was deposited in GenBank database under accession no. HQ537483.
The nucleotide sequence of the putative open reading frame 1 (starting at nt position 97) was translated to a 3,434-aa polypeptide sequence. The nucleotide and putative amino acid sequences were aligned with all complete lineage 2 WNV nt and aa sequences available in GenBank, as well as with representatives of other WNV lineages.
The highest (99.6%) nucleotide identity of the Nea Santa-Greece-2010 sequence was found to the goshawk-Hungary-2004 strain. Only single nucleotide substitutions (n = 44) were detected, equally distributed over the genome. The putative aa sequences of the polyprotein precursor of the 2 viruses were 99.7% identical. The alignment of the putative precursor polypeptide sequences showed aa substitutions unique for the European lineage 2 WNVs. These substitutions were found in the nonstructural proteins (Table).
Several studies have focused on the determination of genetic markers for pathogenicity and virulence of WNV strains. In the New York strain of WNV, envelope protein glycosylation proved to be a molecular determinant of neuroinvasiveness (10). The A30P substitution in the NS2A protein reduced the ability of the virus to inhibit interferon induction (11). The introduction of a T249P amino acid substitution in the NS3 helicase in a low-virulence strain was sufficient to generate a phenotype highly virulent to American crows (12). The C102S mutation in the NS4A protein also influenced virulence and thermosensitivity in a mouse model (13). An adaptive mutation E249G in the same protein reduced virus replication in mouse cells (14). In lineage 2 strains, substitutions in the NS3 protein (S160A and R298G), NS4A protein (A79T), and NS5 protein (T614P, M625R, and M626R) were predicted to be possible virulence markers (15). All these foci were checked in the Nea Santa-Greece-2010 strain, but differences were not found, except for the 249 residue of the NS3 protein. All investigated lineage 2 viruses (including goshawk-Hungary-2004) contain histidine at this locus, while the Greek sequence contains proline, similar to several neuroinvasive lineage-1 WNV strains. Previous experimental studies have attributed this mutation to a higher capacity of the virus to replicate in corvids (12), which likely would result in increased virus transmission rates.
Viruses of lineages 3, 4, and 5 contain aspargine, threonine, and threonine at this locus, respectively (Table). The inferred phylogenetic relationships between the investigated complete genome nucleotide sequences are delineated in a phylogram (Figure). The Nea Santa-Greece-2010 and goshawk-Hungary-2004 viruses form a close, monophyletic group that clusters with neurovirulent lineage 2 strains isolated in South Africa.
Epidemiologic observations of the lineage 2 WNV in Europe during 2004–2010, and the close genetic relatedness of the WNV circulating in Hungary and eastern Austria to the virus identified in Cx. pipiens mosquitoes during the 2010 outbreak in Greece, indicate that, most likely, descendants of the goshawk-Hungary-2004 strain spread southward to the Balkan Peninsula and reached northern Greece. Our data indicate that an independent introduction of a highly similar lineage 2 WNV from Africa to northern Greece is unlikely. The importance of the H249P aa change in the NS3 protein of the Nea Santa-Greece-2010 virus should be verified in experimental studies. This aa change also emphasizes the value of close genetic monitoring of strains involved in additional European WNV outbreaks.
Dr Papa is associate professor of microbiology and head of the National Centre for Arboviruses and Hemorrhagic Fever Viruses in Thessaloniki, Greece. Her major interests are the diagnostics and molecular epidemiology of arboviruses.
We thank the staff of Ecodevelopment S.A., Thessaloniki, for collection and identification of mosquitoes.
The study was partially supported by the grant OTKA K67900, and an agreement signed between the European CDC and the ENIVD network.
- Granwehr BP, Lillibridge KM, Higgs S, Mason PW, Aronson JF, Campbell GA, West Nile virus: where are we now? Lancet Infect Dis. 2004;4:547–56.
- Mackenzie JS, Williams DT. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health. 2009;56:338–56.
- Bakonyi T, Hubálek Z, Rudolf I, Nowotny N. Novel flavivirus or new lineage of West Nile virus, central Europe. Emerg Infect Dis. 2005;11:225–31.
- Vazquez A, Sanchez-Seco MP, Ruiz S, Molero F, Hernandez L, Moreno J, Putative new lineage of West Nile virus, Spain. Emerg Infect Dis. 2010;16:549–52.
- Venter M, Swanepoel R. West Nile virus lineage 2 as a cause of zoonotic neurological disease in humans and horses in southern Africa. Vector Borne Zoonotic Dis. 2010;10:659–64.
- Bakonyi T, Ivanics E, Erdélyi K, Ursu K, Ferenczi E, Weissenböck H, Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis. 2006;12:618–23.
- Papa A, Perperidou P, Tzouli A, Castilletti C. West Nile virus–neutralizing antibodies in humans in Greece. Vector Borne Zoonotic Dis. 2010;10:655–8.
- Papa A, Danis K, Baka A, Bakas A, Dougas G, Lytras T, Ongoing outbreak of West Nile virus infections in humans in Greece, July–August 2010. Euro Surveill. 2010;15:pii:19644.
- Papa A, Xanthopoulou K, Gewehr S, Mourelatos S. Detection of West Nile virus lineage 2 in mosquitoes during a human outbreak in Greece. Clin Microbiol Infect. Epub 2011 Jan 14.
- Shirato K, Miyoshi H, Goto A, Ako Y, Ueki T, Kariwa H, Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J Gen Virol. 2004;85:3637–45.
- Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol. 2006;80:2396–404.
- Brault AC, Huang CY, Langevin SA, Kinney RM, Bowen RA, Ramey WN, A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39:1162–6.
- Wicker JA, Whiteman MC, Beasley DW, Davis CT, Zhang S, Schneider BS, A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006;349:245–53.
- Puig-Basagoiti F, Tilgner M, Bennett CJ, Zhou Y, Muñoz-Jordán JL, García-Sastre A, A mouse cell-adapted NS4B mutation attenuates West Nile virus RNA synthesis. Virology. 2007;361:229–41.
- Botha EM, Markotter W, Wolfaardt M, Paweska JT, Swanepoel R, Palacios G, Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains. Emerg Infect Dis. 2008;14:222–30.
Suggested citation for this article: Papa A, Bakonyi T, Xanthopoulou K, Vázquez A, Tenorio A, Nowotny N. Genetic characterization of West Nile virus lineage 2, Greece, 2010. Emerg Infect Dis [serial on the Internet]. 2011 May [date cited]. http://dx.doi.org/10.3201/eid1705.101759
- Page created: August 19, 2011
- Page last updated: August 19, 2011
- Page last reviewed: August 19, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)